Literature DB >> 16135487

Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.

K C M J Peeters1, C J H van de Velde, J W H Leer, H Martijn, J M C Junggeburt, E Klein Kranenbarg, W H Steup, T Wiggers, H J Rutten, C A M Marijnen.   

Abstract

PURPOSE: Preoperative short-term radiotherapy improves local control in patients treated with total mesorectal excision (TME). This study was performed to assess the presence and magnitude of long-term side effects of preoperative 5 x 5 Gy radiotherapy and TME. Also, hospital treatment was recorded for diseases possibly related to late side effects of rectal cancer treatment. PATIENTS AND METHODS: Long-term morbidity was assessed in patients from the prospective randomized TME trial, which investigated the efficacy of 5 x 5 Gy before TME surgery for mobile rectal cancer. Dutch patients without recurrent disease were sent a questionnaire.
RESULTS: Results were obtained from 597 patients, with a median follow-up of 5.1 years. Stoma function, urinary function, and hospital treatment rates did not differ significantly between the treatment arms. However, irradiated patients, compared with nonirradiated patients, reported increased rates of fecal incontinence (62% v 38%, respectively; P < .001), pad wearing as a result of incontinence (56% v 33%, respectively; P < .001), anal blood loss (11% v 3%, respectively; P = .004), and mucus loss (27% v 15%, respectively; P = .005). Satisfaction with bowel function was significantly lower and the impact of bowel dysfunction on daily activities was greater in irradiated patients compared with patients who underwent TME alone.
CONCLUSION: Although preoperative short-term radiotherapy for rectal cancer results in increased local control, there is more long-term bowel dysfunction in irradiated patients than in patients who undergo TME alone. Rectal cancer patients should be informed on late morbidity of both radiotherapy and TME. Future strategies should be aimed at selecting patients for radiotherapy who are at high risk for local failure.

Entities:  

Mesh:

Year:  2005        PMID: 16135487     DOI: 10.1200/JCO.2005.14.779

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  200 in total

1.  More factors should have been considered.

Authors:  Robert M Hermann
Journal:  Dtsch Arztebl Int       Date:  2010-08-20       Impact factor: 5.594

2.  Chromosomal copy number alterations are associated with persistent lymph node metastasis after chemoradiation in locally advanced rectal cancer.

Authors:  Zhenbin Chen; Zheng Liu; Xutao Deng; Charles Warden; Wenyan Li; Julio Garcia-Aguilar
Journal:  Dis Colon Rectum       Date:  2012-06       Impact factor: 4.585

3.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

Review 4.  Preoperative and adjuvant treatment of localized rectal cancer.

Authors:  Prajnan Das; Christopher H Crane
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

5.  Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer.

Authors:  Philippe Bulens; Alice Couwenberg; Karin Haustermans; Annelies Debucquoy; Vincent Vandecaveye; Marielle Philippens; Mu Zhou; Olivier Gevaert; Martijn Intven
Journal:  Radiother Oncol       Date:  2018-01-31       Impact factor: 6.280

6.  Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.

Authors:  Hiroyuki Kodama; Tetsuji Terazawa; Yasunobu Ishizuka; Hiroki Yukami; Masahiko Aoki; Takahiro Miyamoto; Toshifumi Yamaguchi; Futukaro Shimamoto; Takayuki Kii; Masahiro Goto; Hiroki Hamamoto; Wataru Osumi; Masashi Yamamoto; Keitaro Tanaka; Jyunji Okuda; Kazuhisa Uchiyama; Kazuhide Higuchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 7.  Controversies in the multimodality management of locally advanced rectal cancer.

Authors:  Robert Díaz Beveridge; Dilara Akhoundova; Gema Bruixola; Jorge Aparicio
Journal:  Med Oncol       Date:  2017-04-24       Impact factor: 3.064

Review 8.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

9.  Validation of the standardized index of shape tool to analyze DCE-MRI data in the assessment of neo-adjuvant therapy in locally advanced rectal cancer.

Authors:  Roberta Fusco; Vincenza Granata; Mario Sansone; Daniela Rega; Paolo Delrio; Fabiana Tatangelo; Carmen Romano; Antonio Avallone; Davide Pupo; Marzia Giordano; Roberto Grassi; Vincenzo Ravo; Biagio Pecori; Antonella Petrillo
Journal:  Radiol Med       Date:  2021-05-26       Impact factor: 3.469

10.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.